Published in Drug Metab Dispos on January 13, 2010
Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol (2010) 1.66
Neonatal Fc receptor and IgG-based therapeutics. MAbs (2011) 1.56
A strategy for risk mitigation of antibodies with fast clearance. MAbs (2013) 1.42
Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol (2013) 1.31
Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn. AAPS J (2012) 1.27
Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J (2012) 1.20
The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. MAbs (2015) 1.10
Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J (2012) 1.05
Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor. J Pharmacokinet Pharmacodyn (2012) 1.01
Engineered monoclonal antibody with novel antigen-sweeping activity in vivo. PLoS One (2013) 0.99
Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. World J Biol Chem (2012) 0.96
Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice. MAbs (2012) 0.96
Characterization and screening of IgG binding to the neonatal Fc receptor. MAbs (2014) 0.93
Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector Functions. Front Immunol (2015) 0.86
pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling. J Biol Chem (2014) 0.85
Engineering a monomeric Fc domain modality by N-glycosylation for the half-life extension of biotherapeutics. J Biol Chem (2013) 0.84
Quantitative cumulative biodistribution of antibodies in mice: effect of modulating binding affinity to the neonatal Fc receptor. MAbs (2014) 0.84
Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases. MAbs (2015) 0.83
Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody. MAbs (2014) 0.83
Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys. MAbs (2012) 0.83
A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life. MAbs (2015) 0.81
Targeting FcRn for the modulation of antibody dynamics. Mol Immunol (2015) 0.80
The contribution of cell surface FcRn in monoclonal antibody serum uptake from the intestine in suckling rat pups. Front Pharmacol (2014) 0.80
Absorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions. AAPS J (2012) 0.80
The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies. MAbs (2015) 0.79
Anti-infective immunoadhesins from plants. Plant Biotechnol J (2015) 0.78
Effects of hypertonic buffer composition on lymph node uptake and bioavailability of rituximab, after subcutaneous administration. Biopharm Drug Dispos (2014) 0.78
Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development. MAbs (2015) 0.78
Impact of SPR biosensor assay configuration on antibody: Neonatal Fc receptor binding data. MAbs (2016) 0.77
A single chimpanzee-human neutralizing monoclonal antibody provides post-exposure protection against type 1 and type 2 polioviruses. J Clin Virol (2015) 0.77
Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations. AAPS J (2014) 0.76
Fusion of the mouse IgG1 Fc domain to the VHH fragment (ARP1) enhances protection in a mouse model of rotavirus. Sci Rep (2016) 0.75
Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody. MAbs (2017) 0.75
Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics Syst Pharmacol (2017) 0.75
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol (2008) 5.54
Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med (2011) 2.51
Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Prev (2002) 2.29
Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther (2012) 2.03
A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. Proc Natl Acad Sci U S A (2005) 2.00
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol (2010) 1.94
Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol (2009) 1.93
Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs (2011) 1.66
Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci (2002) 1.58
Enhanced tumor retention of a radiohalogen label for site-specific modification of antibodies. J Med Chem (2013) 1.49
Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci (2002) 1.44
A strategy for risk mitigation of antibodies with fast clearance. MAbs (2013) 1.42
Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res (2009) 1.41
Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem (2011) 1.40
Attenuating lymphocyte activity: the crystal structure of the BTLA-HVEM complex. J Biol Chem (2005) 1.35
Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem (2010) 1.32
Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies. Trends Biotechnol (2010) 1.27
Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm Res (2006) 1.26
Heme oxygenase-1 overexpression protects rat hearts from cold ischemia/reperfusion injury via an antiapoptotic pathway. Transplantation (2002) 1.25
Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? Expert Opin Drug Metab Toxicol (2012) 1.25
Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J (2012) 1.20
Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res (2007) 1.19
Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin Cancer Res (2012) 1.17
Membrane association domains in Ca2+-dependent activator protein for secretion mediate plasma membrane and dense-core vesicle binding required for Ca2+-dependent exocytosis. J Biol Chem (2002) 1.17
Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. J Biol Chem (2010) 1.15
Metabolism of nicotine and cotinine by human cytochrome P450 2A13. Drug Metab Dispos (2004) 1.13
Systemic rather than local heme oxygenase-1 overexpression improves cardiac allograft outcomes in a new transgenic mouse. J Immunol (2003) 1.12
Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J Immunol Methods (2008) 1.11
A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. Cancer Res (2010) 1.10
Structural and functional analysis of a C3b-specific antibody that selectively inhibits the alternative pathway of complement. J Biol Chem (2009) 1.09
Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet (2011) 1.09
Therapeutic peptides. Trends Biotechnol (2003) 1.08
Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol (2008) 1.06
Gene transfer of heme oxygenase-1 and carbon monoxide delivery inhibit chronic rejection. Am J Transplant (2002) 1.04
Redesigning an antibody fragment for faster association with its antigen. Biochemistry (2003) 1.04
Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells. Blood (2006) 1.02
Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade. Blood (2007) 1.01
Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays. Mol Cancer Ther (2008) 1.01
Evaluation of heterophilic antibody blocking agents in reducing false positive interference in immunoassays for IL-17AA, IL-17FF, and IL-17AF. J Immunol Methods (2010) 0.99
Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index. Sci Transl Med (2013) 0.98
Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. J Pharmacokinet Pharmacodyn (2010) 0.97
Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci Transl Med (2013) 0.97
Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice. MAbs (2012) 0.96
Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. World J Biol Chem (2012) 0.96
Establishing a link between amino acid sequences and self-associating and viscoelastic behavior of two closely related monoclonal antibodies. Pharm Res (2011) 0.95
Sequence plasticity in the antigen-binding site of a therapeutic anti-HER2 antibody. J Mol Biol (2002) 0.95
DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma. Mol Cancer Ther (2013) 0.94
Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice. Drug Metab Dispos (2005) 0.93
Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations. AAPS J (2012) 0.92
Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice. Br J Pharmacol (2012) 0.92
Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans. J Pharm Sci (2003) 0.90
Topical application of a novel immunomodulatory peptide, RDP58, reduces skin inflammation in the phorbol ester-induced dermatitis model. J Invest Dermatol (2005) 0.90
Antibody delivery of drugs and radionuclides: factors influencing clinical pharmacology. Ther Deliv (2011) 0.89
Effects of anti-VEGF on predicted antibody biodistribution: roles of vascular volume, interstitial volume, and blood flow. PLoS One (2011) 0.89
Delivery of tea polyphenols to the oral cavity by green tea leaves and black tea extract. Cancer Epidemiol Biomarkers Prev (2004) 0.89
A substrate-phage approach for investigating caspase specificity. Protein J (2004) 0.88
Confounding parameters in preclinical assessment of blood-brain barrier permeation: an overview with emphasis on species differences and effect of disease states. Mol Pharm (2013) 0.88
Comparative physiology of mice and rats: radiometric measurement of vascular parameters in rodent tissues. Mol Pharm (2014) 0.88
Stable "zeta" peptides that act as potent antagonists of the high-affinity IgE receptor. Proc Natl Acad Sci U S A (2002) 0.87
Micro-volume wall-less immunoassays using patterned planar plates. Lab Chip (2013) 0.86
Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. Bioconjug Chem (2008) 0.86
New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine. J Med Chem (2004) 0.86
Convergent recognition of the IgE binding site on the high-affinity IgE receptor. Structure (2004) 0.85
Interplay of dissolution, solubility, and nonsink permeation determines the oral absorption of the Hedgehog pathway inhibitor GDC-0449 in dogs: an investigation using preclinical studies and physiologically based pharmacokinetic modeling. Drug Metab Dispos (2010) 0.85
Development and evaluation of a novel method for preclinical measurement of tissue vascular volume. Mol Pharm (2010) 0.85
CAPS activity in priming vesicle exocytosis requires CK2 phosphorylation. J Biol Chem (2009) 0.85
Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods. J Pharm Sci (2009) 0.84
Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey. Eur J Pharm Sci (2013) 0.83
Technology comparisons for anti-therapeutic antibody and neutralizing antibody assays in the context of an anti-TNF pharmacokinetic study. J Immunol Methods (2009) 0.82
Structure-activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists. Bioorg Med Chem Lett (2010) 0.82
Drug delivery across the blood-brain barrier. Mol Pharm (2013) 0.81
Current challenges and opportunities in nonclinical safety testing of biologics. Drug Discov Today (2013) 0.81
Increases in free, unbound insulin-like growth factor I enhance insulin responsiveness in human hepatoma G2 cells in culture. J Biol Chem (2002) 0.81
Selective alpha4beta7 integrin antagonists and their potential as antiinflammatory agents. J Med Chem (2002) 0.81
Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists. Bioorg Med Chem Lett (2010) 0.81
Anti-neuropilin-1 (MNRP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humans. Pharm Res (2012) 0.80
Sustained delivery of human growth hormone from a novel gel system: SABER. Biomaterials (2002) 0.80
Multiple novel classes of APRIL-specific receptor-blocking peptides isolated by phage display. J Mol Biol (2009) 0.80